[8]
Hopkins, A.L.; Polinsky, A. Knowledge and Intelligence in Drug
Design. Ann. Rep. Med. Chem.Academic Press, 2006, Vol. 41, 425-437.
[9]
Li, J.J. Blockbuster Drugs: The rise and decline of the pharmaceutical industry, 1st ed; Li, J.J., Ed.; Oxford University Press, 2014, Vol. 52, p. 240.
[12]
Campbell, S.F. Molecular recognition and drug design. Quim. Nova, 1991, 14, 195-203.
[16]
Ehrlich, P. Die side chain theory and your opp. In:Muenchener medical weekly; Germany, 1901, pp. 2123-2124.
[17]
Ehrlich, P. Chemotherapeutics: Scientific principles, methods and results. Lancet, 1913, 182, 445-451.
[22]
Ehrlich, P. About bladder disorders after use of the drug 606. Vienna. Klin. Wochenschr., 1910, 23, 1131.
[29]
Le Count, D.J. Chronicles of drug discovery. In: .Atenolol; Brindra, J.S.; Lednicer, D., Eds.; John Wiley & Sons: New York, 1984, Vol. 1, pp. 113-132.
[58]
Steitz, T.A.; Ludwig, M.L.; Quiocho, F.A.; Lipscomb, W.N. The structure of carboxypeptidase A. J. Biol. Chem., 1967, 242, 4462-4668.
[59]
Jackson, E.K. Goodman & Gilman’s: The pharmacological basis of therapeutics. In: Renin and angiotensin; Brunton, L.S.; Lazo, J.S.; Parker, K.L., Eds.; McGraw Hill: New York, 2006, pp. 789-821.
[70]
Lin, J.H.; Drazen, O.; Vacca, J.P. Integration of pharmaceutical discovery and development. The integration of medicinal chemistry, drug metabolism, and pharmaceutical research and development in drug discovery and development: The story of Crixivan®, an HIV protease inhibitor; Borchardt, R.T.; Freidinger, R.M.; Sawyer, T.K; Smith, P.L., Ed.; Kluwer Academic Publishers: New York, 2013, Vol. 11, pp. 233-255.
[73]
Vacca, J.P. HIV Protease Inhibitors Useful for the Treatment of Aids. EP 0 541 168 A1 May 12 1993,
[77]
Bazzini, P.; Wermuth, C.G. The practice of medicinal chemistry. In:Substituent Groups; Wermuth, C.G., Ed.; Elsevier: London, 2008, pp. 431-463.
[97]
Souers, A.J.; Leverson, J.D.; Boghaert, E.R.; Ackler, S.L.; Catron, N.D.; Chen, J.; Dayton, B.D.; Ding, H.; Enschede, S.H.; Fairbrother, W.J.; Huang, D.C.S.; Hymowitz, S.G.; Jin, S.; Khaw, S.L.; Kovar, P.J.; Lam, L.T.; Lee, J.; Maecker, H.L.; Marsh, K.C.; Mason, K.D.; Mitten, M.J.; Nimmer, P.M.; Oleksijew, A.; Park, C.H.; Park, C-M.; Phillips, D.C.; Roberts, A.W.; Sampath, D.; Seymour, J.F.; Smith, M.L.; Sullivan, G.M.; Tahir, S.K.; Tse, C.; Wendt, M.D.; Xiao, Y.; Xue, J.C.; Zhang, H.; Humerickhouse, R.A.; Rosenberg, S.H.; Elmore, S.W. ABT-199, A potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Nat. Med., 2013,
19(2), 202-208.
[
http://dx.doi.org/10.1038/nm.3048] [PMID:
23291630]
[100]
Sofia, M.J. Sofosbuvir: The discovery of a curative therapy for the
treatment of hepatitis C virus. In:Successful Drug Discovery; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2016, pp. 163-188.
[102]
Bronson, J.; Black, A.; Dhar, M.; Ellsworth, B. Robert Merritt, J. To Market, To Market-2013.Annual Reports in Medicinal Chemistry; Elsevier Inc., 2014, Vol. 49, pp. 437-508.
[106]
Rabi, J.A. Methods of Manufacture of 2’Deoxy-Beta-LNucleosides. US 7,582,748 B2, 2005.
[107]
Cleary, D.G.; Reynolds, C.J.; Berrey, M.M.; Hindes, R.G.; William, T.S.; Ray, A.S.; Mo, H.; Oliyai, R.; Stefanidis, D.; Pakdaman, R.; Casteel, M.J. Compositions and methods for treating hepatitis C
virus. US8,889,159 B2, 2014.
[116]
Schmutz, J.; Eichenberger, E. Chronicles of drug discovery. In:Clozapine; Brindra, J.S.; Lednicer, D., Eds.; John Wiley & Sons: New York, 1984, Vol. 1, pp. 39-59.